Inventor
NITTOLI THOMAS
US40 patents
⚠️ This page may combine multiple inventors who share the name “NITTOLI THOMAS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
38 patentsUS10772972B2Sep 15, 2020
Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof
REGENERON PHARMA44 citations97
US10738130B2Aug 11, 2020
Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof
REGENERON PHARMA50 citations97
US9302015B2Apr 5, 2016
Anti-PRLR antibodies and methods for killing PRLR-expressing cells
REGENERON PHARMA82 citations97
US9950076B2Apr 24, 2018
Maytansinoid derivatives, conjugates thereof, and methods of use
REGENERON PHARMA34 citations94
US9951141B2Apr 24, 2018
Antibody-drug conjugates, their preparation and their therapeutic use
REGENERON PHARMA20 citations93
US9475875B2Oct 25, 2016
Anti-EGFRvIII antibodies and uses thereof
REGENERON PHARMA14 citations92
US10570151B2Feb 25, 2020
Biologically active molecules, conjugates thereof, and therapeutic uses
REGENERON PHARMA12 citations86
US10463749B2Nov 5, 2019
Maytansinoid derivatives, conjugates thereof, and methods of use
REGENERON PHARMA4 citations84
US11485793B2Nov 1, 2022
Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof
REGENERON PHARMA4 citations83
US11142578B2Oct 12, 2021
Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof
REGENERON PHARMA6 citations83
US10941208B2Mar 9, 2021
Anti-MUC16 antibodies
REGENERON PHARMA6 citations83
US9545451B2Jan 17, 2017
Anti-PRLR antibodies and methods for killing PRLR-expressing cells
REGENERON PHARMA6 citations83
US11446389B2Sep 20, 2022
Maytansinoid derivatives, conjugates thereof, and methods of use
REGENERON PHARMA1 citations73
US10738124B2Aug 11, 2020
Anti-EGFRvIII antibodies and uses thereof
REGENERON PHARMA3 citations73
US11633501B2Apr 25, 2023
Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof
REGENERON PHARMA3 citations72
US10683354B2Jun 16, 2020
Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cells
REGENERON PHARMA1 citations72
US10106616B2Oct 23, 2018
Antagonist antibodies to human prolactin receptor (PRLR)
REGENERON PHARMA2 citations72
US9688764B2Jun 27, 2017
Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodies
REGENERON PHARMA3 citations72
US12545735B2Feb 10, 2026
Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
REGENERON PHARMA0 citations62
US12419963B2Sep 23, 2025
Diels-Alder conjugation methods
REGENERON PHARMA0 citations62
US12378258B2Aug 5, 2025
Biologically active molecules, conjugates thereof, and therapeutic uses
REGENERON PHARMA0 citations62
US11866502B2Jan 9, 2024
Anti-FGFR2 antibodies and methods of use thereof
REGENERON PHARMA0 citations62
US11608380B2Mar 21, 2023
Anti-EGFRvIII antibodies and uses thereof
REGENERON PHARMA0 citations62
US11345715B2May 31, 2022
Biologically active molecules, conjugates thereof, and therapeutic uses
REGENERON PHARMA0 citations62
US10047160B2Aug 14, 2018
Anti-EGFRvIII antibodies and uses thereof
REGENERON PHARMA1 citations62
US12570764B2Mar 10, 2026
Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof
REGENERON PHARMA0 citations61
US12564640B2Mar 3, 2026
Protein-antiviral compound conjugates
REGENERON PHARMA0 citations61
US12497460B2Dec 16, 2025
Anti-MSR1 antibodies and methods of use thereof
REGENERON PHARMA0 citations61
US11752214B2Sep 12, 2023
Protein-antiviral compound conjugates
REGENERON PHARMA0 citations61
US11377502B2Jul 5, 2022
Anti-MSR1 antibodies and methods of use thereof
REGENERON PHARMA1 citations61
US12583939B2Mar 24, 2026
Bispecific antigen binding molecules that bind HER2, and methods of use thereof
REGENERON PHARMA0 citations60
US11958910B2Apr 16, 2024
Bispecific antigen binding molecules that bind HER2, and methods of use thereof
REGENERON PHARMA1 citations60
US12297207B2May 13, 2025
Maytansinoid derivatives, conjugates thereof, and methods of use
REGENERON PHARMA0 citations52
US11814428B2Nov 14, 2023
Anti-PTCRA antibody-drug conjugates and uses thereof
REGENERON PHARMA0 citations52
US10752690B2Aug 25, 2020
Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
REGENERON PHARMA0 citations51
US10526344B2Jan 7, 2020
Amino acid acylation reagents and methods of using the same
REGENERON PHARMA0 citations46
US11596635B2Mar 7, 2023
Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
REGENERON PHARMA0 citations44
US11666658B2Jun 6, 2023
Rifamycin analogs and antibody-drug conjugates thereof
REGENERON PHARMA0 citations38